natgillin/translations-raw huggingface dataset:
Doctors should monitor the levels of tacrolimus in the blood to check that they stay within predefined ranges. 
Zdravnik mora spremljati koncentracije takrolimusa v krvi, da bi se tako prepričal, da te ostajajo znotraj predhodno določenih razponov.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) ADVAGRAF EPAR summary for the public 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) ADVAGRAF Povzetek EPAR za javnost
Patients and doctors must be careful when other medicines (including some herbal remedies) are taken at the same time as Advagraf, as there may be a need to adjust the dose of Advagraf or the dose of the medicine it is taken with. 
Bolniki in zdravniki morajo biti pazljivi pri jemanju drugih zdravil (vključno z nekaterimi zeliščnimi zdravili) sočasno z zdravilom Advagraf, saj utegne biti potrebno prilagoditi odmerek zdravila Advagraf ali zdravila, s katerim se zdravilo Advagraf jemlje.
Advagraf is for long-term use. 
Zdravilo Advagraf je predvideno za dolgotrajno uporabo.
In the European Union (EU), it has been available as capsules under the name Prograf or Prograft (depending on the country). 
V Evropski uniji (EU) je na voljo v obliki kapsul z imenom Prograf ali Prograft (odvisno od države).
Because tacrolimus and Prograf/Prograft have already been used in the EU, the company presented the results of studies that had been carried out with Prograf/Prograft previously, as well as data from the published literature. 
Ker se takrolimus in zdravilo Prograf/Prograft v EU že uporabljata, je podjetje predložilo rezultate študij, ki so bile predhodno izvedene z zdravilom Prograf/Prograft, ter podatke iz objavljene literature.
The Committee recommended that Advagraf be given marketing authorisation. 
Odbor je zato priporočil, da se za zdravilo Advagraf odobri dovoljenje za promet.
Tacrolimus acts on some special cells in the immune system called T-cells that are primarily responsible for attacking the transplanted organ (organ rejection). 
Takrolimus učinkuje na nekatere posebne celice v imunskem sistemu, imenovane celice T, ki so v prvi vrsti odgovorne za napadanje presajenega organa (zavrnitev organa).
Doses are calculated based on the patient's weight. 
Odmerki se izračunajo na osnovi bolnikove telesne mase.
It is available as prolongedreleased capsules containing tacrolimus (0.5 mg: yellow and orange; 1 mg: white and orange; 5 mg: greyish-red and orange). 
Na voljo je v obliki kapsul s podaljšanim sproščanjem, ki vsebujejo takrolimus (0,5 mg rumene in oranžne barve, 1 mg bele in oranžne barve, 5 mg sivkasto-rdeče in oranžne barve).
Patients also received mycophenolate mofetil (another medicine used in the prevention of rejection). 
Bolniki so prejemali tudi mikofenolat mofetil (drugo zdravilo, ki se uporablja za preprečevanje zavrnitve).
‘Prolonged-release' means that tacrolimus is released slowly from the capsule over a few hours. 
Podaljšano sproščanje pomeni, da se takrolimus iz kapsule sprošča počasi več ur.
The most common side effects with Advagraf (seen in more than 1 patient in 10) are tremor (shaking), headache, nausea (feeling sick), diarrhoea, kidney problems, hyperglycaemia (raised blood glucose levels), diabetes, hyperkalaemia (raised blood potassium levels), hypertension (high blood pressure) and insomnia (difficulty sleeping). 
Najpogostejši neželeni učinki zdravila Advagraf (opaženi pri več kot 1 bolniku izmed 10) so tremor (tresenje), glavobol, navzea (občutek slabosti), driska, težave z ledvicami, hiperglikemija (povečane ravni glukoze v krvi), sladkorna bolezen, hiperkaliemija (povečane ravni kalija v krvi), hipertenzija (visok krvni tlak) in nespečnost.
What benefit has Advagraf shown during the studies? 
Kakšne koristi je zdravilo Advagraf izkazalo med raziskavami?
Advagraf can also be used to treat organ rejection in adult patients when other immunosuppressive medicines are not effective. 
Zdravilo Advagraf se lahko uporablja tudi za zdravljenje zavrnitev organov pri odraslih bolnikih, kadar druga imunosupresivna zdravila niso učinkovita.
What is the risk associated with Advagraf? 
Kakšna tveganja so povezana z zdravilom Advagraf?
The main measure of effectiveness was the number of patients in whom the transplant failed (as measured by looking at, for example, the need for a repeat transplant or a return to dialysis) after one year's treatment. 
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih se je presaditev po enoletnem zdravljenju izkazala za neuspešno (merilo je bila na primer potreba po ponovni presaditvi ali vrnitvi na dializo).
The percentages were 15% in the patients treated with Prograf/Prograft, and 17% in those treated with ciclosporin. 
Pri bolnikih, ki so prejemali zdravilo Prograf/Prograft, je bil ta delež 15 %, pri bolnikih, ki so prejemali ciklosporin, pa 17 %.
Advagraf should not be used in people who may be hypersensitive (allergic) to tacrolimus, to macrolide antibiotics (such as erythromycin) or to any of the other ingredients. 
Zdravila Advagraf ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) takrolimus, makrolidne antibiotike (kot je na primer eritromicin) ali na katerokoli drugo sestavino zdravila.
Treatment with Advagraf should only be prescribed by doctors who have experience in the management of transplant patients. 
Zdravljenje z zdravilom Advagraf sme predpisati samo zdravnik z izkušnjami z zdravljenjem bolnikov s presadki.
Further shorter studies were also carried out in 119 kidney transplant patients and 129 liver transplant patients, looking at how Advagraf is absorbed by the body in comparison to Prograf/Prograft. 
Izvedene so bile tudi nadaljnje krajše študije s 119 bolniki s presajenimi ledvicami in 129 bolniki s presajenimi jetri, v katerih so preučevali, kako telo absorbira zdravilo Advagraf v primerjavi z zdravilom Prograf/Prograft.
Advagraf is a medicine containing the active substance tacrolimus. 
Advagraf je zdravilo, ki vsebuje zdravilno učinkovino takrolimus.
This allows Advagraf to be given once a day, whereas Prograf/Prograft is given twice a day. 
Pri zdravilu Advagraf zato zadošča en odmerek dnevno, medtem ko se zdravilo Prograf/Prograft daje dvakrat dnevno.
Advagraf is very similar to Prograf/Prograft, but the way the medicine is made has been changed so that the active substance is released more slowly from the capsule than it is in Prograf/Prograft. 
Zdravilo Advagraf je zelo podobno zdravilu Prograf/Prograft, vendar je izdelano na drugačen način, in sicer tako da se zdravilna učinkovina iz kapsule sprošča počasneje kot pri zdravilu Prograf/Prograft.
It also presented the results of a clinical study in 668 kidney transplant patients comparing the use of Advagraf with that of Prograf/Prograft or ciclosporin (another immunosuppressive medicine used in the prevention of rejection). 
Predložilo je tudi rezultate klinične študije s 668 bolniki s presajenimi ledvicami, v kateri so primerjali uporabo zdravila Advagraf z uporabo zdravila Prograf/Prograft ali ciklosporina (drugega imunosupresivnega zdravila, ki se uporablja za preprečevanje zavrnitve).
See the Package Leaflet for details. 
Za več podrobnosti glejte Navodilo za uporabo.
In liver transplant, the starting dose is 0.10 to 0.20 mg/kg. 
Pri presaditvi jeter je začetni odmerek 0,10 do 0,20 mg/kg.
The shorter studies in kidney and liver transplant patients showed that Advagraf and Prograf/Prograft have comparable absorption in the body. 
Krajše študije z bolniki s presaditvijo ledvic in jeter so pokazale, da se zdravili Advagraf in Prograf/Prograft primerljivo absorbirata v telesu.
After one year, 14% of the patients receiving Advagraf had experienced organ failure. 
Po enem letu je prišlo do odpovedi organa pri 14 % bolnikov, ki so prejemali zdravilo Advagraf.
In the prevention of rejection, the dose of Advagraf to use depends on the type of transplant the patient has received. 
Odmerek zdravila Advagraf, uporabljen za preprečevanje zavrnitve, je odvisen od vrste presadka, ki ga je bolnik prejel.
Why has Advagraf been approved? 
Zakaj je bilo zdravilo Advagraf odobreno?
For the full list of all side effects reported with Advagraf, see the Package Leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Advagraf, glejte Navodilo za uporabo.
In kidney transplant, the starting dose is 0.20 to 0.30 mg per kilogram body weight. 
Pri presaditvi ledvic je začetni odmerek 0,20 do 0,30 mg na kilogram telesne mase.
The Committee for Medicinal Products for Human Use (CHMP) decided that Advagraf's benefits are greater than its risks for the prophylaxis of transplant rejection in adult kidney and liver allograft recipients, and in the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je sklenil, da so koristi zdravila Advagraf pri preprečevanju zavrnitve presadka pri odraslih prejemnikih alogenskega presadka ledvic ali jeter ter pri zdravljenju zavrnitve alogenskega presadka, odporne na zdravljenje z drugimi imunosupresivnimi zdravili, pri odraslih bolnikih večje od z njim povezanih tveganj.
When treating rejection, these same doses may be used in kidney and liver transplants. 
Isti odmerki se lahko pri presaditvah ledvic in jeter uporabljajo za zdravljenje zavrnitve.
The full EPAR for Advagraf can be found here. 
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Advagraf je na voljo tukaj.
What is Advagraf used for? 
Za kaj se zdravilo Advagraf uporablja?
How has Advagraf been studied? 
Kako je bilo zdravilo Advagraf raziskano?
Tacrolimus, the active substance in Advagraf, is an immunosuppressive agent. 
Zdravilna učinkovina zdravila Advagraf, takrolimus, je imunosupresivna učinkovina.
What is Advagraf? 
Kaj je zdravilo Advagraf?
Advagraf is used in adult patients who have had a kidney or liver transplant, to prevent rejection (when the immune system attacks the transplanted organ). 
Zdravilo Advagraf se uporablja za preprečevanje zavrnitve presadka (ko imunski sistem napade presajen organ) pri odraslih bolnikih, pri katerih je bila opravljena presaditev ledvic ali jeter.
How is Advagraf used? 
Kako se zdravilo Advagraf uporablja?
How does Advagraf work? 
Kako zdravilo Advagraf deluje?
Starting doses are 0.10 to 0.30 mg/kg in other types of transplant (heart, lung, pancreas or intestine). 
Pri drugih vrstah presadkov (srce, pljuča, trebušna slinavka ali črevesje) pa znašajo začetni odmerki 0,10 do 0,30 mg/kg.
Consequently, newborn infants should be monitored carefully. 
Posledično je treba takšne novorojenčke skrbno nadzirati.
Date of first authorisation: 01 September 2010 Date of latest renewal: 05 May 2015 
Datum prve odobritve: 01. september 2010 Datum zadnjega podaljšanja: 05. maj 2015
* See subsection “Falls” below 
*Glejte spodaj podpoglavje "Padci"
Reported estimated doses were between 15 and 400 mg. 
Prijavljeni ocenjeni odmerki so bili med 15 in 400 mg.
Patients with rapid cycling were excluded from these studies. 
Bolniki s hitrejšimi cikli so bili iz teh študij izključeni.
Paediatric population (children and adolescents) 
Pediatrična populacija (otroci in mladostniki)
If you are unable to take this medicine as is described below, the treatment may not be effective for you. 
Če tega zdravila ne morete jemati tako, kot je opisano v nadaljevanju, zdravljenje pri vas morda ne bo učinkovito.
This medicine belongs to a group of medicines called antipsychotics. 
To zdravilo sodi v skupino zdravil, ki jim pravimo antipsihotiki.
Available pharmacokinetic data are described in section 5.2. 
Farmakokinetični podatki, ki so na voljo, so opisani v poglavju 5.2.
Keep the tablet under your tongue until it dissolves. 
Tableto držite pod jezikom, dokler se ne raztopi.
Patients from the two pivotal 3 week trials were studied for a further 9 weeks an extension trial. 
Bolnike iz dveh ključnih 3-tedenskih preskušanj so dodatno preiskovali še v 9-tedenskem podaljšanem preskušanju.
One dose should be taken in the morning and one dose should be taken in the evening. 
En odmerek vzemite zjutraj in enega zvečer.
Drynam Road, Swords, Co. Dublin Ireland 
Drynam Road, Swords, Co. Dublin Irska
Close medical supervision and monitoring should continue until the patient recovers. 
Skrben zdravniški nadzor in spremljanje bolnika naj trajata, dokler bolnik ne okreva.
Following an initial more rapid distribution phase, the terminal half-life of asenapine is approximately 24 h. 
Po začetni hitrejši fazi porazdelitve znaša končna razpolovna doba asenapina približno 24 ur.
- To ensure optimal absorption, place the tablet under the tongue and wait until it dissolves completely (Figure 3). 
- Da bi zagotovili optimalno absorpcijo zdravila, položite tableto pod jezik in počakajte, da se popolnoma raztopi (slika 3).
What Sycrest is and what it is used for 
Kaj je zdravilo Sycrest in za kaj ga uporabljamo
Pharmacotherapeutic group: Psycholeptics, antipsychotics, ATC code: N05AH05 
Farmakoterapevtska skupina: Psiholeptiki, antipsihotiki, oznaka ATC: N05AH05
The mechanism of action of asenapine is not fully understood. 
Mehanizem delovanja asenapina še ni v celoti pojasnjen.
In the early stages of treatment, some people may faint, especially when getting up from a lying or sitting position. 
Na začetku zdravljenja lahko nekateri bolniki omedlijo, še posebej ob vstajanju iz ležečega ali sedečega položaja.
In elderly patients (between 65 and 85 years of age), exposure to asenapine is approximately 30 % higher than in younger adults. 
Pri starejših bolnikih (starih med 65 in 85 let) je izpostavljenost asenapinu približno za 30 % večja kot pri drugih mlajših odraslih bolnikih.
Do not take Sycrest If you are allergic to asenapine or any of the other ingredients of this medicine (listed in section 6). 
Ne jemljite zdravila Sycrest Če ste alergični na asenapin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
This leaflet was last revised in {month/YYYY}. 
Navodilo je bilo nazadnje revidirano {MM/LLLL}.
Other side effects reported with this medicine include: 
Drugi neželeni učinki, o katerih so poročali pri uporabi tega zdravila, so:
Since Sycrest can lower blood pressure, care should be taken when Sycrest is taken with other medicines that lower blood pressure. 
Ker lahko zdravilo Sycrest zniža krvni tlak, je potrebna previdnost pri jemanju zdravila Sycrest z drugimi zdravili, ki tudi znižujejo krvni tlak.
All ADRs are listed by system organ class and frequency; very common (≥ 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1,000 to < 1/100), rare ( 1/10,000 to < 1/1,000) and not known (cannot be estimated from the available data). 
Vsi neželeni učinki so razvrščeni po organskih sistemih in po pogostnosti; zelo pogosti (≥ 1/10), pogosti ( 1/100 do < 1/10), občasni ( 1/1.000 do < 1/100), redki ( 1/10.000 do < 1/1.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Asenapine is rapidly distributed and has a large volume of distribution (approximately 20-25 L/kg), indicating extensive extravascular distribution. 
Asenapin se hitro porazdeli in ima velik porazdelitveni volumen (približno 20-25 l/kg), kar kaže na njegovo obsežno porazdelitev zunaj žilja.
Patients should be advised to avoid alcohol while taking Sycrest. 
Bolnikom je treba svetovati, naj se med jemanjem zdravila Sycrest izogibajo alkoholu.
Other serious ADRs are discussed in more detail in section 4.4. 
Drugi resni neželeni učinki so podrobneje opisani v poglavju 4.4.
There are no adequate data from the use of Sycrest in pregnant women. 
Ni zadostnih podatkov o uporabi zdravila Sycrest pri nosečnicah.
Packs may contain 20, 60 or 100 tablets. 
Pakiranja lahko vsebujejo 20, 60 ali 100 tablet.
In a mass balance study, the majority of the radioactive dose was recovered in urine (about 50 %) and faeces (about 40 %), with only a small amount excreted in faeces (5-16 %) as unchanged compound. 
V študiji masne bilance so večino radioaktivnega odmerka našli v urinu (približno 50 %) in v blatu (približno 40 %), le majhna količina se ga je izločila v obliki nespremenjene spojine z blatom (5-16 %).
Sycrest should not be used during pregnancy unless the clinical condition of the woman requires treatment with asenapine and only if the potential benefit outweighs the potential risk to the foetus. 
Zdravila Sycrest se med nosečnostjo ne sme uporabljati, razen če zdravstveno stanje ženske zahteva zdravljenje z asenapinom in le, če njegove možne koristi odtehtajo potencialno tveganje za plod.
Asenapine demonstrated superior efficacy to placebo in the reduction of manic symptoms over 3 weeks. 
Asenapin je pokazal večjo učinkovitost od placeba kar zadeva zmanjšanje maničnih simptomov v obdobju 3 tednov.
- The exact amount is shown on your Sycrest tablet pack. 
- Natančna količina je navedena na pakiranju tablet Sycrest.
Long term safety in this population was explored in a 50-week, open-label, uncontrolled extension study. 
Dolgoročno varnost so pri tej populaciji raziskali v odprti, nenadzorovani 50-tedenski podaljšani študiji.
Check with your doctor or pharmacist before taking Sycrest: 
Posvetujte se z zdravnikom ali farmacevtom, preden začnete jemati zdravilo Sycrest:
Serious hypersensitivity reactions have been reported. 
Poročali so o resnih preobčutljivostnih reakcijah.
The tablet will dissolve in saliva within seconds. 
Tableta se bo v nekaj sekundah raztopila v slini.
Do not use this medicine after the expiry date which is stated on the blister and on the carton. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in škatli.
In the same study, treatment with paroxetine 20 mg daily decreased the DX/DM ratio to 0.032. 
V isti študiji je zdravljenje s paroksetinom v odmerku 20 mg na dan zmanjšalo razmerje DX/DM na 0,032.
Children and adolescents Sycrest is not recommended for use in patients below the age of 18 years. 
Otroci in mladostniki Uporabe zdravila Sycrest ne priporočamo pri bolnikih, mlajših od 18 let.
If this combination is deemed necessary, the lowest effective dose of each treatment should be prescribed. 
Če menite, da je njihova sočasna uporaba resnično potrebna, morate bolniku predpisati najmanjši še učinkovit odmerek vsakega od zdravil.
A statistically significant difference between asenapine and placebo was seen as early as day 2. 
Statistično pomembna razlika med asenapinom in placebom se je pokazala že 2. dan.
N.V. Organon, Kloosterstraat 6, NL-5349 AB Oss, The Netherlands 
Organon, Kloosterstraat 6, NL-5349 AB Oss, Nizozemska
Asenapine was excreted in milk of rats during lactation. 
Asenapin se je izločal v mleko pri podganah v času laktacije.
In in vitro assays asenapine acts as an antagonist at these receptors. 
V testiranjih in vitro se asenapin obnaša kot antagonist teh receptorjev.
The table is based on adverse reactions reported during clinical trials and/or post-marketing use. 
Ta preglednica temelji na neželenih učinkih, ki so bili poročani v kliničnih preskušanjih in/ali v obdobju trženja zdravila.
What you need to know before you take Sycrest 
Kaj morate vedeti, preden boste vzeli zdravilo Sycrest
Sycrest may cause low blood pressure. 
Zdravilo Sycrest lahko povzroči padec krvnega tlaka.
If you stop taking Sycrest, you will lose the effects of this medicine. 
Če prenehate jemati zdravilo Sycrest, boste s tem izgubili tudi njegove zdravilne učinke.
Long term efficacy could not be established in a 50-week, uncontrolled, open-label extension trial. 
Dolgoročne učinkovitosti v odprtem, nenadzorovanem 50-tedenskem podaljšanem preskušanju niso mogli dokazati.
Asenapine is highly bound (95 %) to plasma proteins, including albumin and α1-acid glycoprotein. 
Asenapin se v velikem odstotku (95 %) veže na plazemske beljakovine, vključno z albuminom in α1-kislim glikoproteinom.
You should not stop taking this medicine, unless your doctor tells you as your symptoms may return. 
Z jemanjem zdravila torej ne smete prenehati, če vam to ne svetuje zdravnik, saj se vam simptomi lahko povrnejo.
Manufacturer Organon (Ireland) Ltd. Drynam Road, Swords Co. Dublin, Ireland 
Izdelovalec Organon (Ireland) Ltd. Drynam Road, Swords Co. Dublin, Irska
Also contact your doctor immediately if any of these conditions develops or worsens while using Sycrest. 
Z zdravnikom se takoj posvetujte tudi, če se vam katera od teh bolezni ali motenj pojavi ali poslabša med uporabo zdravila Sycrest.
In addition, histopathological examination of the eyes from dogs treated chronically with asenapine did not reveal any signs of ocular toxicity, demonstrating the absence of a phototoxic hazard. 
Poleg tega tudi histopatološki pregled oči psov, kronično zdravljenih z asenapinom, ni pokazal nobenih znakov toksičnosti za oči, kar dokazuje, da ni tveganja za fototoksičnost zdravila.
Repeat-dose toxicity studies in rat and dog showed mainly dose-limiting pharmacological effects, such as sedation. 
Študije toksičnosti pri ponavljajočih se odmerkih pri podganah in psih so pokazale predvsem farmakološke učinke za omejitev odmerka, na primer sedacijo.
Your dose may need to be adjusted. 
Morda bo potrebna prilagoditev odmerka.
The European Medicines Agency has deferred the obligation to submit the results of studies with Sycrest in one or more subsets of the paediatric population in bipolar I disorder (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila obvezo za predložitev rezultatov študij z zdravilom Sycrest za eno ali več podskupin pediatrične populacije pri bipolarni motnji I (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Elderly patients are particularly at risk for experiencing orthostatic hypotension (see section 4.8). 
Pri starostnikih je še posebej veliko tveganje za pojav ortostatske hipotenzije (glejte poglavje 4.8).
However, based on its receptor pharmacology, it is proposed that the efficacy of asenapine is mediated through a combination of antagonist activity at D2 and 5-HT2A receptors. 
Na podlagi farmakologije njegovih receptorjev pa predpostavljamo, da njegovo delovanje temelji na kombinaciji antagonističnega delovanja na receptorje D2 in 5-HT2A.
Sycrest is not advised if you are unable to take the tablet as described below. 
Zdravila Sycrest ne priporočamo osebam, ki tablet ne morejo jemati tako, kot je opisano spodaj.
Very common side effects (may affect more than 1 in 10 people) - anxiety - sleepiness 
Zelo pogosti neželeni učinki (pojavijo se lahko pri več kot 1 od 10 bolnikov) - tesnoba - zaspanost
The dose can be increased to 10 mg twice daily based on individual clinical response and tolerability. 
Odmerek se lahko zviša na 10 mg dvakrat na dan na podlagi kliničnega odziva in prenašanja zdravila posameznika.
Do not take Sycrest while you are pregnant, unless your doctor tells you so. 
Zdravila Sycrest ne smete jemati med nosečnostjo, razen če vam to svetuje vaš zdravnik.
In subcutaneous carcinogenicity studies in rats and mice, no increases in tumour incidences were observed. 
V študijah subkutane kancerogenosti pri podganah in miših niso opazili nobenega povečanja incidence tumorjev.
Cerebrovascular events have been reported in patients treated with asenapine but there is no evidence of any excess incidence over what is expected in adults between 18 and 65 years of age. 
Pri bolnikih, zdravljenih z asenapinom, so poročali o možgansko-žilnih dogodkih, vendar ni dokazov za večjo incidenco od tiste, ki je že pričakovana pri odraslih, starih od 18 do 65 let.
- Gently remove the tablet (Figure 2). 
- Tableto previdno vzemite ven (slika 2).
- The other ingredients are gelatin and mannitol (E421). 
- Pomožni snovi sta želatina in manitol (E421).
The less than proportional increase of Cmax and AUC with dose may be attributed to limitations in the absorption capacity from the oral mucosa following sublingual administration. 
Manj kot sorazmerno povečevanje vrednosti Cmax in AUC z odmerkom lahko pripišemo omejitvam v absorpcijski kapaciteti ustne sluznice pri podjezični uporabi.
Other medicines and Sycrest 
Druga zdravila in zdravilo Sycrest
Sycrest with food, drink and alcohol Do not eat or drink for 10minutes after taking this medicine. 
Zdravilo Sycrest skupaj s hrano, pijačo in alkoholom Še 10 minut po zaužitju tega zdravila ne smete jesti ali piti.